|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 肿瘤部位或决定结肠癌DNA错配修复功能缺陷的预后影响显示文摘目前对于接受氟尿嘧啶、亚叶酸钙及奥沙利铂(FOLFOX)辅助化疗方案治疗的结肠癌患者,DNA错配修复功能缺陷(dMMR)与预后间的联系尚不明了。美国梅奥诊所的Frank A.Sinicrope博士等人进行了一项临床试验,研究人员在2,580份肿瘤患者的蛋白芯片中,检测到314份(12%)肿瘤患者的蛋白芯片存在 dMMR,其中分别有49.3%及10.6%存在BRAFV600E或KRAS突变。尽管从整体而言,MMR状态并非预后预测因素,但研究同时发现,MMR与原发肿瘤部位及淋巴结分期( N1 v N2)间存在显著的相互作用。对突变情况及协变量校正后,研究人员发现,与准确进行MMR邻近肿瘤相对的dMMR可获得良好的DFS结局,但远端肿瘤的dMMR与良好的DFS结局无关。 N2肿瘤患者不能通过dMMR取得生存获益。BRAFV600 E突变或KRAS突变均为较差DFS的独立相关因素。根据肿瘤部位相互作用观察到的MMR得到了III期结肠癌患者独立队列的验证。 | Sinicrope FA Mahoney MR Smyrk TC | 2013 | 中华结直肠疾病电子杂志2013，2，4： | 27 |
| 2 | Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis显示文摘To assess the value of magnetic resonance elastography(MRE) in detecting advanced fibrosis/cirrhosis in autoimmune hepatitis(AIH).METHODS In this retrospective study, 36 patients(19 treated and 17 untreated) with histologically confirmed AIH and liver biopsy performed within 3 mo of MRE were identified at a tertiary care referral center. Liver stiffness(LS) with MRE was calculated by a radiologist, and inflammation grade and fibrosis stage in liver biopsy was assessed by a pathologist in a blinded fashion. Two radiologistsevaluated morphological features of cirrhosis on conventional magnetic resonance imaging(MRI). Accuracy of MRE was compared to laboratory markers and MRI for detection of advanced fibrosis/cirrhosis.RESULTS Liver fibrosis stages of 0, 1, 2, 3 and 4 were present in 4, 6, 7, 6 and 13 patients respectively. There were no significant differences in distribution of fibrosis stage and inflammation grade between treated and untreated patient groups. LS with MRE demonstrated stronger correlation with liver fibrosis stage in comparison to laboratory markers for chronic liver disease(r = 0.88 vs-0.48-0.70). A trend of decreased mean LS in treated patients compared to untreated patients was observed(3.7 k Pa vs 3.84 k Pa) but was not statistically significant. MRE had an accuracy/sensitivity/specificity/positive predictive value/negative predictive value of 0.97/90%/100%/100%/90% and 0.98/92.3%/96%/92.3%/96% for detection of advanced fibrosis and cirrhosis, respectively. The performance of MRE was significantly better than laboratory tests for detection of advanced fibrosis(0.97 vs 0.53-0.80, P < 0.01), and cirrhosis(0.98 vs 0.58-0.80, P < 0.01) and better than conventional MRI for diagnosis of cirrhosis(0.98 vs 0.78, P = 0.002).CONCLUSION MRE is a promising modality for detection of advanced fibrosis and cirrhosis in patients with AIH with superior diagnostic accuracy compared to laboratory assessment and MRI. | Jin Wang Neera Malik Meng Yin Thomas C Smyrk Albert J Czaja Richard L Ehman Sudhakar K Venkatesh | 2017 | World Journal of Gastroenterology2017，23，5： | 15 |
| 3 | Colonoscopy surveillance for high risk polyps does not always prevent colorectal cancer显示文摘AIM To determine the frequency and risk factors for colorectal cancer(CRC) development among individuals with resected advanced adenoma(AA)/traditional serrated adenoma(TSA)/advanced sessile serrated adenoma(ASSA). METHODS Data was collected from medical records of 14663 subjects found to have AA, TSA, or ASSA at screening or surveillance colonoscopy. Patients with inflammatory bowel disease or known genetic predisposition for CRC were excluded from the study. Factors associated with CRC developing after endoscopic management of high risk polyps were calculated in 4610 such patients who had at least one surveillance colonoscopy within 10 years following the original polypectomy of the incident advanced polyp. RESULTS84/4610(1.8%) patients developed CRC at the polypectomy site within a median of 4.2 years(mean 4.89 years), and 1.2%(54/4610) developed CRC in a region distinct from the AA/TSA/ASSA resection site within a median of 5.1 years(mean 6.67 years). Approximately, 30%(25/84) of patients who developed CRC at the AA/TSA/ASSA site and 27.8%(15/54) of patients who developed CRC at another site had colonoscopy at recommended surveillance intervals. Increasing age; polyp size; male sex; right-sided location; high degree of dysplasia; higher number of polyps resected; and piecemeal removal were associated with an increased risk for CRC developmentat the same site as the index polyp. Increasing age; right-sided location; higher number of polyps resected and sessile endoscopic appearance of the index AA/TSA/ASSA were significantly associated with an increased risk for CRC development at a different site. CONCLUSION Recognition that CRC may develop following AA/TSA/ASSA removal is one step toward improving our practice efficiency and preventing a portion of CRC related morbidity and mortality. | Mohamad A Mouchli Lidia Ouk Marianne R Scheitel Alisha P Chaudhry Donna Felmlee-Devine Diane E Grill Shahrooz Rashtak Panwen Wang Junwen Wang Rajeev Chaudhry Thomas C Smyrk Ann L Oberg Brooke R Druliner Lisa A Boardman | 2018 | World Journal of Gastroenterology2018，24，8： | 5 |
| 4 | Swallowed Fluticasone Improves Histologic but Not Symptomatic Response of Adults With Eosinophilic Esophagitis显示文摘 | Jeffrey A. Alexander Kee Wook Jung Amindra S. Arora Felicity Enders David A. Katzka Gail M. Kephardt Hirohito Kita Lori A. Kryzer Yvonne Romero Thomas C. Smyrk Nicholas J. Talley | 2012 | Clinical Gastroenterology and Hepatology2012，，7： | 3 |
| 5 | Risk of Intestinal Cancer in Inflammatory Bowel Disease: A Population-Based Study From Olmsted County, Minnesota显示文摘 | Tine Jess Edward V. Loftus Fernando S. Velayos W. Scott Harmsen Alan R. Zinsmeister Thomas C. Smyrk Cathy D. Schleck William J. Tremaine L. Joseph Melton Pia Munkholm William J. Sandborn | 2006 | Gastroenterology2006，，4： | 3 |
| 6 | Differences in Clinical Profile and Relapse Rate of Type 1 Versus Type 2 Autoimmune Pancreatitis显示文摘 | Raghuwansh P. Sah Suresh T. Chari Rahul Pannala Aravind Sugumar Jonathan E. Clain Michael J. Levy Randall K. Pearson Thomas C. Smyrk Bret T. Petersen Mark D. Topazian Naoki Takahashi Michael B. Farnell Santhi S. Vege | 2010 | Gastroenterology2010，，1： | 3 |
| 7 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 8 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 9 | Esophageal eosinophilia with dysphagia显示文摘 | Stephen E. A. Attwood Thomas C. Smyrk Tom R. Demeester James B. Jones | 1993 | Digestive Diseases and Sciences1993，，： | 2 |
| 10 | Epidemiology of Eosinophilic Esophagitis Over Three Decades in Olmsted County, Minnesota显示文摘 | Ganapathy A. Prasad Jeffery A. Alexander Cathy D. Schleck Alan R. Zinsmeister Thomas C. Smyrk Richard M. Elias G. Richard Locke Nicholas J. Talley | 2009 | Clinical Gastroenterology and Hepatology2009，，10： | 2 |
| 11 | A Controlled Trial of Gluten-Free Diet in Patients With Irritable Bowel Syndrome-Diarrhea: Effects on Bowel Frequency and Intestinal Function显示文摘 | Maria I. Vazquez–Roque Michael Camilleri Thomas Smyrk Joseph A. Murray Eric Marietta Jessica O’Neill Paula Carlson Jesse Lamsam Denise Janzow Deborah Eckert Duane Burton Alan R. Zinsmeister | 2013 | Gastroenterology2013，，5： | 2 |
| 12 | Occurrence of and risk factors for complications after endoscopic dilation in eosinophilic esophagitis显示文摘 | Kee Wook Jung Nancy Gundersen Jana Kopacova Amindra S. Arora Yvonne Romero David Katzka Dawn Francis Julie Schreiber Ross A. Dierkhising Nicholas J. Talley Thomas C. Smyrk Jeffrey A. Alexander | 2011 | Gastrointestinal Endoscopy2011，，1： | 2 |
| 13 | Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes显示文摘 | Frank A. Sinicrope Qian Shi Thomas C. Smyrk Stephen N. Thibodeau Rodrigo Dienstmann Justin Guinney Brian M. Bot Sabine Tejpar Mauro Delorenzi Richard M. Goldberg Michelle Mahoney Daniel J. Sargent Steven R. Alberts | 2014 | Gastroenterology2014，，： | 2 |
| 14 | Idiopathic Chronic Pancreatitis With Periductal Lymphoplasmacytic Infiltration: Clinicopathologic Features of 35 Cases显示文摘 | Kenji Notohara Lawrence J. Burgart Dhiraj Yadav Suresh Chari Thomas C. Smyrk | 2003 | The American Journal of Surgical Pathology2003，，8： | 2 |
| 15 | Molecular genetics and clinical-pathology features of hereditary nonpolyposis cancer显示文摘 | Smyrk T Lynch JF | 1998 | Oncology1998，55，2： | 1 |
| 16 | Molecular genetics and clinical-pathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome):istorical journey from pedigree anecdote to molecular genetic confirmation显示文摘 | Lynchh T Smyrk T Lynch JF | 1998 | Oncol1998，55，： | 1 |
| 17 | Diagnosis of Autoimmune Pancreatitis: The Mayo Clinic Experience显示文摘 | Suresh T. Chari Thomas C. Smyrk Michael J. Levy Mark D. Topazian Naoki Takahashi Lizhi Zhang Jonathan E. Clain Randall K. Pearson Bret T. Petersen Santhi Swaroop Vege Michael B. Farnell | 2006 | Clinical Gastroenterology and Hepatology2006，，8： | 1 |
| 18 | Value of serum IgG4 in the di-agnosis of autoimmune pancreatitis and in distinguishing it from pa-nereatic cancer显示文摘 | Ghazale A Chari ST Smyrk TC’ | 2007 | Am J Gastroenterol2007，102，8： | 1 |
| 19 | Defective DNA mismatch repair in long-term (>or= 3years) survivors with pancreatic cancer显示文摘 | MAPLE JT SMYRK TC BOARDMAN LA | 2005 | Pancreatology2005，5，2： | 1 |
| 20 | Autoimmune pancreatitis and IgG4- related systemic diseases 显示文摘 | Zhang L Smyrk T C | 2010 | Int J Clin Exp Pathol2010，3，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员